Related Experiment Video

Updated: Jul 23, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors

C N Mork1, D V Faller, R A Spanjaard

  • 1Cell and Molecular Biology Program and Department of Microbiology, Cancer Research Center, 715 Albany St, R903, Boston University School of Medicine, Boston, MA 02118, USA.

Current Pharmaceutical Design
|April 28, 2005
PubMed

Insights

Histone deacetyltransferase (HDAC) inhibitors show promise as anti-cancer agents by regulating gene accessibility. These compounds can inhibit tumor cell proliferation and induce apoptosis, offering a new epigenetic therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Cancer Therapeutics

Background:

  • Gene accessibility in condensed DNA is crucial for cellular function and is regulated by histone modifications like acetylation.
  • Histone acetylation, catalyzed by histone acetyl transferases (HATs) and histone deacetyltransferases (HDACs), influences gene transcription.
  • Histone deacetylation leads to transcriptional repression by increasing DNA-histone electrostatic interactions.

Purpose of the Study:

  • To explore the role of histone deacetyltransferase (HDAC) inhibitors in cancer therapy.
  • To understand the mechanisms by which HDAC inhibitors affect cell cycle progression, differentiation, and apoptosis.
  • To highlight the potential of HDAC inhibitors as a novel epigenetic antitumor therapeutic strategy.

Main Methods:

  • Review of existing literature on histone modifications and HDAC inhibitor mechanisms.
  • Analysis of studies investigating the effects of HDAC inhibitors on cell cycle arrest (G1 and G2/M phases).
  • Examination of preclinical and clinical trial data on HDAC inhibitors as anti-cancer agents.

Main Results:

  • HDAC inhibition maintains histone acetylation, leading to altered gene regulation.
  • HDAC inhibitors can inhibit cell proliferation, induce differentiation, and promote apoptosis in tumor cells.
  • Reactivation of silenced tumor suppressor genes by HDAC inhibitors has been observed.

Conclusions:

  • HDAC inhibitors represent a promising class of anti-cancer agents with a novel epigenetic mechanism of action.
  • Targeting specific HDAC isozymes and further understanding their anti-neoplastic effects are key for advancing this therapeutic strategy.
  • HDAC inhibitors offer a new avenue for epigenetic antitumor therapy.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...